BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-exelixis-stellar-303-304-mid-2026-readout@catalyst-calendar.local
DTSTAMP:20260720T200612Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:Exelixis zanzalintinib STELLAR-304三期非透明细胞RCC顶线数据窗口
DESCRIPTION:Exelixis披露STELLAR-304三期研究预计2026年中读出顶线结果，评估zanzalintinib联合nivolumab一线治疗晚期非透明细胞肾细胞癌，若成功可能影响RCC靶向/IO联合治疗格局。\\nImpact score: 71\\nExpected: 顶线PFS/ORR数据将影响zanzalintinib作为下一代TKI和非透明细胞RCC潜在首个系统疗法定位。\\nAffected: EXEL(subject\, unknown\, score 86)\; XBI(etf\, mixed\, score 56)\; BMY(customer\, mixed\, score 55)\; MRK(peer\, mixed\, score 54)\\nSources: Exelixis 2026 preliminary results and pipeline update: https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-preliminary-fiscal-year-2025-financial\\nExelixis Q1 2026 Results: https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-first-quarter-2026-financial-results-and\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-exelixis-stellar-303-304-mid-2026-readout
CATEGORIES:guidance\,US\,clinical-readout\,Phase 3\,RCC\,CRC\,TKI\,topline\,VEGF\,IO\,Phase-3\,oncology
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Exelixis zanzalintinib STELLAR-304三期非透明细胞RCC顶线数据窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Exelixis zanzalintinib STELLAR-304三期非透明细胞RCC顶线数据窗口
END:VALARM
END:VEVENT
END:VCALENDAR